Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 04:19 ET | Source: Research and Markets

Tysabri (natalizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Tysabri (natalizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...
September 30, 2024 03:00 ET | Source: Global Market Insights Inc.

Multiple Sclerosis Therapeutic Market to hit USD 38.1 billion by 2032, says Global Market Insights Inc.

Selbyville, Delaware, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Multiple Sclerosis Therapeutic Market size was valued at approximately USD 25.5 billion in 2023. Projections indicate a growth rate of...
November 09, 2023 07:59 ET | Source: Pasithea

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS
December 22, 2022 06:03 ET | Source: Research and Markets

2022 TYSABRI (Natalizumab) Report: A Recombinant Humanized IgG4 Monoclonal Antibody Produced in Murine Myeloma Cells - Drug Insight and Market Forecasts to 2032

Dublin, Dec. 22, 2022 (GLOBE NEWSWIRE) -- The "TYSABRI (Natalizumab), Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering."TYSABRI (Natalizumab),...
September 12, 2019 05:00 ET | Source: Biogen Inc.

New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognitionAn analysis of data...
January 03, 2019 07:30 ET | Source: Biogen Inc.

First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis

Study will provide the first randomized, controlled efficacy and safety data of every-six-week dosing for natalizumab CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- The first patient has been...